Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia - PubMed (original) (raw)
Review
Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia
Joshua P Metlay. Infect Dis Clin North Am. 2004 Dec.
Abstract
In contrast to the tremendous number of articles and meetings devoted to elucidating the mechanisms of antibacterial drug resistance and describing the emergence of drug resistance patterns, little research has been completed on the impact of bacterial drug resistance on clinical outcomes. Moreover.among the studies that have been completed, the better-designed studies generally have failed to detect an effect of most current levels of antibacterial drug resistance on clinical outcomes for patients who have CAP. Yet, practice patterns are shifting in response to the perception that current levels of drug resistance necessitate changes in treatment patterns. This is unfortunate because it severely limits one's ability to continue to monitor the effectiveness of available therapies in light of changing patterns of antibacterial drug resistance. If levels of drug resistance continue to rise, it is likely that outcomes from those drug treatments will be affected adversely. In this regard, the recent licensing of a 7-valent pneumococcal conjugate vaccine for infants and young children may have an important effect on future trends in antibacterial drug resistance. The vaccine reduces childhood carriage of vaccine serotypes,which are among the most common serotypes found among drug-resistant isolates, and may reduce transmission of these serotypes to adults [65]. In conclusion, antibacterial drug resistance has not reduced substantially the effectiveness of first-line treatments for CAP. Whether levels of drug resistance will continue to increase or decline is unknown. Therefore,carefully designed outcomes studies likely will continue to be essential to help define optimal therapy for patients who have CAP.
Similar articles
- Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Asche C, et al. J Antimicrob Chemother. 2008 May;61(5):1162-8. doi: 10.1093/jac/dkn073. Epub 2008 Feb 29. J Antimicrob Chemother. 2008. PMID: 18310136 - Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Martin M, et al. J Antimicrob Chemother. 2007 May;59(5):977-89. doi: 10.1093/jac/dkm033. Epub 2007 Mar 29. J Antimicrob Chemother. 2007. PMID: 17395688 - Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP 3rd, Zhanel GG. Lynch JP 3rd, et al. Semin Respir Crit Care Med. 2009 Apr;30(2):210-38. doi: 10.1055/s-0029-1202939. Epub 2009 Mar 18. Semin Respir Crit Care Med. 2009. PMID: 19296420 Review. - Overview of recent studies of community-acquired pneumonia.
Higgins K, Singer M, Valappil T, Nambiar S, Lin D, Cox E. Higgins K, et al. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S150-6. doi: 10.1086/591397. Clin Infect Dis. 2008. PMID: 18986282 Review. - Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP. Rapp RP. Postgrad Med. 2002 Sep;112(3 Suppl):12-7. doi: 10.3810/pgm.09.2002.suppl19.100. Postgrad Med. 2002. PMID: 19667590
Cited by
- Interspecies recombination, not de novo mutation, maintains virulence after β-lactam resistance acquisition in Streptococcus pneumoniae.
Nishimoto AT, Dao TH, Jia Q, Ortiz-Marquez JC, Echlin H, Vogel P, van Opijnen T, Rosch JW. Nishimoto AT, et al. Cell Rep. 2022 Dec 13;41(11):111835. doi: 10.1016/j.celrep.2022.111835. Cell Rep. 2022. PMID: 36516783 Free PMC article. - Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.
Martí-Carvajal AJ, Conterno LO. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2016 Nov 14;11(11):CD005598. doi: 10.1002/14651858.CD005598.pub4. Cochrane Database Syst Rev. 2016. PMID: 27841444 Free PMC article. Review. - Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson BD, Fernandes P. Oldach D, et al. Antimicrob Agents Chemother. 2013 Jun;57(6):2526-34. doi: 10.1128/AAC.00197-13. Epub 2013 Mar 18. Antimicrob Agents Chemother. 2013. PMID: 23507282 Free PMC article. Clinical Trial. - Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.
English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu ZQ, Jenta TR, Flavin MT, Eiznhamer DA. English ML, et al. Antimicrob Agents Chemother. 2012 Apr;56(4):2037-47. doi: 10.1128/AAC.05596-11. Epub 2012 Jan 30. Antimicrob Agents Chemother. 2012. PMID: 22290969 Free PMC article. Clinical Trial. - Changing needs of community-acquired pneumonia.
Ramirez JA, Anzueto AR. Ramirez JA, et al. J Antimicrob Chemother. 2011 Apr;66 Suppl 3(Suppl 3):iii3-9. doi: 10.1093/jac/dkr094. J Antimicrob Chemother. 2011. PMID: 21482567 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous